Nanox.AI
FDA-cleared AI for detecting incidental cardiac, bone, and liver findings on routine CT scans.
Nanox.AI delivers a proven, focused suite for cardiac, bone, and liver incidental findings—ideal for mid-to-large health systems with existing CT volume. Its targeted pathology set is a strength for opportunistic screening but a limitation if you need broader AI coverage. For an integrated, vendor-neutral solution with real outcomes data, it's a strong pick.
Verified 3d ago · liveness 68/100 · cite: rightaichoice.com/tools/nanox-ai
- Radiologists identifying asymptomatic chronic disease from routine CT scans
- Large health systems (IDNs) improving preventive care and generating revenue
- Imaging centers offering value-added screening without additional scans
- Clinical researchers studying opportunistic screening outcomes
- Clinics needing AI for emergency findings like stroke or pulmonary embolism
- Single-physician practices with low CT volume (cost may not justify ROI)
- Hospitals already using a comprehensive multi-pathology AI platform
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Nanox.AI if you need AI for emergency findings (stroke/PE), have low CT volume where ROI won't materialize, lack PACS/EMR integration, or want a comprehensive multi-pathology AI platform.
Pricing is not public; you'll need to negotiate with sales, and the initial licensing and implementation fees may be significant.
Nanox.AI is positioned for large health systems and imaging centers that process high CT volumes, where the cost per scan becomes justifiable through revenue generation and improved outcomes. It's not designed for small practices; more affordable entry points exist with point solutions like HeartFlow or Zebra Medical, but they lack the integrated multi-pathology coverage.
In short
Nanox.AI — FDA-cleared AI for detecting incidental cardiac, bone, and liver findings on routine CT scans. Best for Radiologists identifying asymptomatic chronic disease from routine CT scans, Large health systems (IDNs) improving preventive care and generating revenue, Imaging centers offering value-added screening without additional scans. Contact Sales pricing.
What people actually say about Nanox.AI — is it worth it?
We ran a structured research pass across product reviews, community discussions, and post-purchase forum threads to surface the patterns vendors won't publish themselves. Below: the recurring strengths, the hidden costs people mention most, and the cohort that consistently regrets adopting this tool.
8 mentions across 1 source (YouTube) · researched Aug 24, 2026.
- +FDA 510(k) cleared for opportunistic screening with strong clinical backing
- +Demonstrated real-world impact: Corewell Health found nearly 4,000 new cardiac patients
- +Vendor-neutral and PACS/EMR integrations streamline radiology workflow
- +Automates detection of incidental findings without extra radiation or patient visits
- +Over 500 million images processed and 22 granted patents show technical maturity
- −Parent company's going-concern status raises fears of product abandonment
- −Very little independent user discussion or reviews available online
- −Stock crash and cash cliff dominate any conversation about the tool
- −No hands-on community feedback on ease of use or actual workflow
- −Videos are largely about stock speculation, not product usage
- • Implementation and integration costs likely not included in base pricing
- • Potential annual maintenance or subscription fees not publicly disclosed
Viability Score
How well maintained and how widely used is Nanox.AI? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: September 2026
How we score →Key Features
- Coronary artery calcium detection on non-gated CT
- Osteoporosis screening via vertebral height loss assessment
- Bone mineral density measurement on chest and abdominal CT
- Liver density quantification on contrast and non-contrast CT
- Automated detection of incidental findings
- PACS integration for seamless workflow
- EMR integration for streamlined patient care
- Automated report generation into reporting systems
- Vendor-neutral across PACS systems
- FDA 510(k) cleared
- CE marked
- Opportunistic screening without additional imaging
About Nanox.AI
Nanox.AI is a suite of FDA-cleared AI solutions designed to detect incidental findings associated with chronic conditions—coronary artery calcification, vertebral fractures, bone mineral density loss, and fatty liver disease—on routine CT scans. The platform integrates with PACS, EMR, and reporting systems to flag asymptomatic patients for preventive care. Key products include HealthCCSng for coronary artery calcium detection on non-gated CT, HealthOST for osteoporosis screening via vertebral height loss and bone density measurement, and HealthFLD for liver density quantification on contrast and non-contrast scans. With over 30 million patient records and 500 million images processed, backed by 22 granted patents and 7 FDA 510(k) clearances, Nanox.AI has demonstrated real-world impact—Corewell Health identified nearly 4,000 new cardiac patients in 2023 using the cardiac solution, and the ADOPT study showed improved spine fracture detection over NHS averages. The AI is vendor-neutral and automates report generation and EMR connectivity, enabling opportunistic screening without additional radiation or patient visits. Unlike general AI radiology platforms, Nanox.AI focuses specifically on incidental findings from CT scans performed for other reasons, making it a targeted tool for large health systems aiming to improve preventive care and generate revenue.
Behind the Verdict
Nanox.AI stands out for its sharp focus on opportunistic screening—detecting chronic conditions that show up incidentally on CT scans performed for other reasons. The suite's three main tools (HealthCCSng, HealthOST, HealthFLD) cover the most common incidental findings and are FDA-cleared, which is a meaningful trust signal in medical AI. If you're a large health system with high CT volume, this could surface thousands of previously undiagnosed conditions and create new revenue streams through preventive care programs. The vendor-neutral integration with PACS, EMR, and reporting systems means it slots into your existing workflow without locking you into a specific imaging vendor. One of the standout proof points is Corewell Health's experience: they identified nearly 4,000 new cardiac patients in a single year using HealthCCSng. That's tangible ROI. However, the platform is not a general-purpose radiology AI—it won't flag strokes or pulmonary embolisms. If you need a broader pathology coverage, you'd pair it with other tools. Also, pricing is opaque; you'll need to engage with sales, and the cost structure likely assumes a certain scan volume to justify the investment. Smaller practices with low CT volume may find it hard to hit ROI. The lack of a self-service API also limits flexibility for teams that want to build custom integrations or run their own validation studies. Overall, if your organization processes enough CTs and is serious about preventive cardiology, bone health, and fatty liver screening, Nanox.AI is a credible, evidence-backed choice.
Researching Nanox.AI? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Nanox.AI actually fits — and what changes day-one when you adopt it.
Wants to implement opportunistic screening to identify undiagnosed cardiac disease across the system's CT volume.
Outcome: Deploys HealthCCSng, integrates with PACS and EMR, and within months flags hundreds of at-risk patients, leading to new preventive cardiology referrals and improved population health metrics.
Wants to differentiate by offering value-added screening without extra scans.
Outcome: Uses the full suite to add coronary calcium, osteoporosis, and fatty liver findings to every routine CT report, generating additional revenue per study and attracting referring physicians seeking comprehensive reports.
Studying the impact of AI-detected incidental findings on patient outcomes.
Outcome: Uses Nanox.AI's quantitative outputs to analyze cohorts, publish findings on early detection, and secure funding for expanded screening programs based on the data.
Use Cases
- Identify asymptomatic coronary artery disease on routine chest CT scans
- Flag vertebral compression fractures in CT scans of the thoracic or lumbar spine
- Quantify hepatic steatosis in abdominal CTs for early fatty liver diagnosis
- Enable opportunistic osteoporosis screening using CT bone density estimation
- Generate revenue by adding screening findings to existing CT volume
- Improve population health management by detecting undiagnosed chronic conditions
Models Under the Hood
as of 2026-08-30
Limitations
- Nanox.AI targets only cardiac, bone, and liver incidental findings—it won't flag emergent conditions like stroke or pulmonary embolism.
- The platform requires integration with PACS and EMR systems; without those, it's not functional.
- Pricing is not public; you must contact sales, and the cost model likely requires a minimum CT volume to achieve ROI.
- Performance may need calibration for non-standard CT acquisition protocols.
- There is no self-service API for custom integrations or direct developer access.
as of 2026-08-30
Verification history
We have re-verified Nanox.AI 17 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-checked, vendor evidence unchanged
Showing the 6 most recent of 17 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Nanox.AI's pricing actually pencils out — and where peers do it cheaper.
Nanox.AI is positioned for large health systems and imaging centers that process high CT volumes, where the cost per scan becomes justifiable through revenue generation and improved outcomes. It's not designed for small practices; more affordable entry points exist with point solutions like HeartFlow or Zebra Medical, but they lack the integrated multi-pathology coverage.
Setup time & first value
How long it actually takes to get something useful out of Nanox.AI — broken out by persona, not the marketing-page minute.
For a large health system, expect 3-6 months for procurement, IT integration, and staff training. For an imaging center with existing PACS/EMR, initial pilot can be live in 4-8 weeks. Full deployment across multiple sites may take longer.
Switching to or from Nanox.AI
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From manual chart review or no screening: Integrate Nanox.AI with your existing PACS and EMR; the AI will run automatically on every CT, flagging incidental findings without additional human effort.
- ↗To a more comprehensive AI radiology platform: Export the AI-generated findings from your reporting system and transition to a multi-pathology vendor that covers additional modalities.
Integrations
Resources & Guides
- Resourcenanox.vision
AI for Incidental Findings Detection in CT Scans | Nanox
Nanox.AI solutions detect asymptomatic findings in cardiac, liver, and bone from routine CT scans to support preventive care management.
- Resourcenanox.vision
Clinical Evidence, White Papers & Imaging Resources | Nanox
Explore clinical publications, white papers, and research on digital tomosynthesis and AI-assisted CT analysis for Nanox imaging solutions.
Tutorials & Learning
Official links
Frequently Asked Questions
Categories
Topics
Used Nanox.AI? Help shape our editorial sentiment research.